Diagnosing mesothelioma requires a combination of imaging scans, tissue biopsy, and specialized lab analysis. No single blood test or scan can confirm the disease on its own. The process typically moves from initial imaging to tissue sampling, then to microscopic and molecular analysis that identifies the exact type and stage of the cancer.
Initial Imaging: What Scans Reveal
The diagnostic process usually begins with a chest X-ray, which can detect thickening of the pleura (the thin membrane lining the lungs and chest wall), calcium deposits, or fluid buildup between the chest wall and lungs. These findings aren’t enough to confirm mesothelioma, but they raise enough suspicion to warrant more detailed imaging.
A CT scan comes next, providing a more precise picture of the location and extent of any abnormal tissue. Doctors use CT to measure tumor thickness and determine how far changes have spread along the pleura or into surrounding structures. A PET scan is often added to distinguish between scar tissue and active cancer, since asbestos exposure can cause scarring that mimics tumors on a CT scan. MRI is sometimes used to evaluate whether the cancer has reached the diaphragm, the thin muscle separating the chest from the abdomen.
For people with known asbestos exposure, doctors may recommend regular chest X-rays or CT scans as a monitoring strategy, even before symptoms appear. But imaging alone cannot distinguish mesothelioma from other conditions. A tissue sample is always needed.
Biopsy: The Only Way to Confirm
Pleural biopsy remains the standard diagnostic method for mesothelioma. There are several ways to obtain tissue, and the choice depends on the tumor’s location and the patient’s overall health. The six main biopsy techniques include open surgical biopsy, surgical thoracoscopy (camera-guided surgery under general anesthesia), medical thoracoscopy (a less invasive camera procedure), CT-guided needle biopsy, ultrasound-guided needle biopsy, and blind needle biopsy.
Many national guidelines favor surgical thoracoscopy because it provides large, high-quality tissue samples. However, it requires general anesthesia and is more invasive. Medical thoracoscopy, performed with lighter sedation, achieves sensitivity above 90% in most studies, which is comparable to the surgical approach. This makes it a practical alternative for many patients, particularly those who may not tolerate a more aggressive procedure.
For peritoneal mesothelioma, which develops in the lining of the abdomen rather than the chest, the diagnostic path is slightly different. Patients are typically referred to a gastroenterologist. If fluid has accumulated in the abdomen (a condition called ascites), a doctor can drain it using a needle inserted through the skin under local anesthesia. This fluid can be tested for cancer cells, though a tissue biopsy of the thickened peritoneal lining is still needed for a definitive diagnosis. CT scans of the abdomen provide information about tumor location and thickness.
What Happens in the Lab
Once tissue is removed, a pathologist examines it under a microscope to determine whether cancer is present and, if so, which subtype. Mesothelioma falls into three main categories: epithelioid, sarcomatoid, and biphasic (a mix of both). This distinction matters because each subtype behaves differently. Epithelioid mesothelioma, the most common form, tends to grow more slowly and responds better to treatment. Sarcomatoid tumors are more aggressive. In biphasic cases, prognosis depends largely on what proportion of the tissue is sarcomatoid.
Pathologists also evaluate features like cell division rate and the presence of dead tissue within the sample. These characteristics can be translated into a grading score that helps predict how the cancer will progress.
Immunohistochemistry: Telling Mesothelioma Apart
One of the trickiest aspects of diagnosing mesothelioma is distinguishing it from cancers that look similar under a microscope, particularly lung adenocarcinoma, which can spread to the pleura and mimic mesothelioma’s appearance. Pathologists solve this problem using immunohistochemistry, a technique that stains tissue samples with antibodies to detect specific proteins on cell surfaces.
A panel of protein markers is used. Mesothelial markers like calretinin, CK5/6, WT1, and D2-40 light up in mesothelioma cells. Epithelial markers like MOC-31, BerEP4, and claudin-4 light up in carcinomas that originated elsewhere. When comparing epithelioid mesothelioma to lung adenocarcinoma, calretinin is highly sensitive (it catches most true cases), while WT1 and the loss of a protein called BAP1 are exceptionally specific (when they’re positive, the diagnosis is almost certainly mesothelioma). No single marker is perfect, which is why pathologists use multiple markers together.
Blood Tests and Biomarkers
Blood-based biomarkers exist but have significant limitations. The most widely used is a protein called soluble mesothelin, marketed under the brand name MesoMark. A meta-analysis of studies involving over 700 mesothelioma patients found that the related blood test (serum SMRP) had 64% sensitivity and 89% specificity. A separate analysis of mesothelin itself showed just 32% sensitivity with 95% specificity. In practical terms, this means a positive result is strongly suggestive of mesothelioma, but a negative result misses many true cases. That low sensitivity makes it unreliable as a screening tool.
Where blood tests prove more useful is in monitoring. MesoMark levels tend to drop after surgery and rise again during disease progression, making them helpful for tracking whether treatment is working or the cancer is returning. In about 82% of patients with progressive disease, MesoMark levels increased over time.
Staging the Cancer
Once mesothelioma is confirmed, doctors stage it using the TNM system. This evaluates three things: how far the primary tumor has spread within the pleura and into nearby structures (T), whether cancer has reached nearby lymph nodes (N), and whether it has spread to distant organs like the bones, liver, or the opposite lung (M).
Stage I mesothelioma is confined to the pleura on one side of the chest, with the total measured thickness of the pleural tumor not exceeding 12 millimeters across three spots on imaging. Higher stages reflect progressively deeper invasion into surrounding tissues, lymph node involvement, and eventually distant spread. Staging directly determines treatment options, including whether surgery is feasible.
Liquid Biopsy: A New Layer of Detection
A recent clinical trial at Johns Hopkins introduced ultra-sensitive liquid biopsy analysis for operable mesothelioma, the first time this technology has been applied to the disease. The technique uses whole genome sequencing to detect fragments of tumor DNA circulating in the blood, known as ctDNA.
In the trial, this method detected microscopic signs of cancer that imaging missed entirely. Patients whose ctDNA dropped by 95% or more during treatment, or became undetectable before surgery, had significantly longer survival. Persistent ctDNA was linked to early disease progression even when scans appeared stable. While this technology is not yet part of routine diagnosis, it represents a meaningful step toward catching recurrence and treatment failure earlier than current tools allow.